Financial reports
10-Q
2024 Q2
Quarterly report
9 Aug 24
10-Q
2024 Q1
Quarterly report
13 May 24
ARS
2023 FY
Annual report to shareholders
23 Apr 24
10-K
2023 FY
Annual report
15 Mar 24
10-Q
2023 Q3
Quarterly report
2 Nov 23
10-Q
2023 Q2
Quarterly report
3 Aug 23
10-Q
2023 Q1
Quarterly report
4 May 23
ARS
2022 FY
Annual report to shareholders
1 May 23
10-K
2022 FY
Annual report
15 Feb 23
10-Q
2022 Q3
Quarterly report
3 Nov 22
Current reports
8-K
Termination of a Material Definitive Agreement
2 Jul 24
8-K
Termination of a Material Definitive Agreement
11 Jun 24
8-K
Submission of Matters to a Vote of Security Holders
7 Jun 24
8-K
Departure of Directors or Certain Officers
3 Jun 24
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
12 Feb 24
8-K
Cost Associated with Exit or Disposal Activities
4 Jan 24
8-K
AlloVir Provides Updates on Phase 3 Clinical Development Program for Posoleucel, an Allogeneic Virus-Specific T Cell Therapy
22 Dec 23
8-K
AlloVir Reports Third Quarter 2023 Financial Results
2 Nov 23
8-K
AlloVir Reports Second Quarter 2023 Financial Results
3 Aug 23
8-K
AlloVir Announces Proposed Public Offering of Common Stock
26 Jun 23
Registration and prospectus
RW
Registration withdrawal request
15 Feb 24
424B5
Prospectus supplement for primary offering
22 Jun 23
424B5
Prospectus supplement for primary offering
21 Jun 23
S-8
Registration of securities for employees
15 Feb 23
S-3
Shelf registration
15 Feb 23
424B5
Prospectus supplement for primary offering
27 Jul 22
POS AM
Prospectus update (post-effective amendment)
18 Feb 22
POS AM
Prospectus update (post-effective amendment)
10 Feb 22
S-8
Registration of securities for employees
10 Feb 22
POSASR
Automatic shelf registration (post-effective amendment)
10 Feb 22
Proxies
DEFA14A
Additional proxy soliciting materials
23 Apr 24
DEF 14A
Definitive proxy
23 Apr 24
DEFA14A
Additional proxy soliciting materials
31 Mar 23
DEF 14A
Definitive proxy
31 Mar 23
PRE 14A
Preliminary proxy
21 Mar 23
DEFA14A
Additional proxy soliciting materials
6 Apr 22
DEF 14A
Definitive proxy
6 Apr 22
DEFA14A
Additional proxy soliciting materials
12 Apr 21
DEF 14A
Definitive proxy
12 Apr 21
Other
EFFECT
Notice of effectiveness
1 Mar 22
EFFECT
Notice of effectiveness
30 Jul 20
CERT
Certification of approval for exchange listing
29 Jul 20
CORRESP
Correspondence with SEC
28 Jul 20
CORRESP
Correspondence with SEC
27 Jul 20
CORRESP
Correspondence with SEC
27 Jul 20
CORRESP
Correspondence with SEC
27 Jul 20
UPLOAD
Letter from SEC
24 Jul 20
CORRESP
Correspondence with SEC
23 Jul 20
CORRESP
Correspondence with SEC
20 Jul 20
Ownership
4
Vikas Sinha
4 Oct 24
4
Edward Miller
4 Oct 24
4
Diana Brainard
4 Oct 24
4
Brett R Hagen
4 Oct 24
144
Notice of proposed sale of securities
3 Oct 24
144
Notice of proposed sale of securities
3 Oct 24
144
Notice of proposed sale of securities
3 Oct 24
144
Notice of proposed sale of securities
3 Oct 24
4
Diana Brainard
22 Aug 24
144
Notice of proposed sale of securities
21 Aug 24